Brain Metastasis Clinical Trial
Official title:
Neuropsychological and Oncological Outcomes After Hippocampal-Sparing Prophylactic Cranial Irradiation in Postoperative Patients With Pathologically Nodal Positive Non-Small-Cell Lung Cancer - A Prospective Follow-up Study
Background. During the clinical course of patients with locoregionally advanced non-small-cell lung cancer (LA-NSCLC) who have undergone aggressive treatment, brain metastasis (BM) is a frequent seen pattern of disease relapse, which cannot be ignored. It still remains unresolved whether prophylactic cranial irradiation (PCI) via whole brain radiotherapy (WBRT) should be recommended for NSCLC patients with stage III or pathologically nodal positive disease. Actually, PCI would significantly decrease the incidence of BM; however, potential WBRT-related neurocognitive function (NCF) sequelae are indeed a concern, which has made PCI seldom applied in clinical practice. In terms of the time course of WBRT-induced NCF decline, it might vary considerably according to the specific domains which are selected to be measured. Early neurocognitive decline principally involve impairments of episodic memory, which has been significantly associated with functions of the hippocampus. This study thus aims to explore the impact of PCI on the subsequent risk of developing BM and the multi-domain neurobehavioral functions in our eligible patients. Methods. Potentially eligible subjects are postoperative NSCLC patients with a status of pathologically nodal metastasis (pN+). Patients randomly assigned to the PCI arm will undergo the course of hippocampal-sparing PCI after they complete the fourth course of adjuvant platinum-based chemotherapy. Radiotherapy dose will be 3000 cGy in 15 fractions during three weeks. Except for the administration of hippocampal-sparing PCI, patients assigned to the observation arm should receive the same baseline and follow-up brain imaging examinations and neurocognitive assessments as those in PCI arm. Accordingly, a battery of neuropsychological measures, which includes 7 standardized neuropsychological tests (e.g., executive functions, verbal & non-verbal memory, working memory, and psychomotor speed), is used to evaluate neurobehavioral functions for our registered patients. Expected results. This randomized controlled study aims to verify that the incidence of BM still can significantly be reduced by hippocampal-sparing PCI; additionally, NCF preservation regarding neurobehavioral assessments might also be achieved by hippocampal-sparing PCI as compared with the observation arm without PCI. No matter what the final results present, it is believed that this randomized controlled trial (RCT) will provide us solid evidence concerning the exact value of hippocampal-sparing PCI in our patient setting.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT01913067 -
Evaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer and NSCLC
|
Phase 2 | |
| Completed |
NCT02662725 -
Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain Metastases
|
Phase 2 | |
| Completed |
NCT00406835 -
Prospective Randomized Trial Between WBRT Plus SRS Versus SRS Alone for 1-4 Brain Metastases
|
Phase 3 | |
| Completed |
NCT01724801 -
Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer
|
Phase 3 | |
| Completed |
NCT00219297 -
Study of Patupilone in Patients With Brain Metastasis From Non-small Cell Lung Cancer
|
Phase 2 | |
| Withdrawn |
NCT02328300 -
FLT PET/MR for Evaluation of Pseudoprogression in Patients With Brain Lesions
|
||
| Terminated |
NCT01324635 -
Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors
|
Phase 1 | |
| Terminated |
NCT01894633 -
Study of Whole-brain Irradiation With Chloroquine for Brain Metastases
|
Phase 2 | |
| Recruiting |
NCT02681549 -
Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer
|
Phase 2 | |
| Terminated |
NCT02279992 -
Pilot Study of Vardenafil and Carboplatin in Patients With Gliomas and Brain Metastases
|
Early Phase 1 | |
| Completed |
NCT02913534 -
Hypofractionated Stereotactic Radiation Therapy of Brain Metastases: Evaluation of Whole-brain Radiotherapy
|
N/A | |
| Completed |
NCT01942980 -
Evaluation of the Efficacy of Hippocampal Avoidance on the Cognitive Toxicity of Whole-Brain Radiation Therapy After Surgical Resection of Single Brain Metastasis of Breast Cancer
|
Phase 3 | |
| Terminated |
NCT01363557 -
Assess the Efficacy of Whole Brain Radiation Therapy in Lung Cancer Patients With Brain Metastasis
|
N/A | |
| Active, not recruiting |
NCT05102747 -
Stereotactic Radiotherapy in Oligometastatic Brain Disease: a Randomised Phase III Study Comparing Hypofractionated Stereotactic Radiation Therapy (3*10 Gy) to the Historical Single-dose Radiosurgery (1*20 to 25 Gy) With Medico-economic Evaluation.
|
N/A | |
| Recruiting |
NCT01891708 -
VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer
|
N/A | |
| Completed |
NCT01508221 -
Evaluation of the Use of Trental and Vitamin E For Prophylaxis of Radiation Necrosis
|
Phase 2 | |
| Completed |
NCT00587964 -
Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
|
Phase 2 | |
| Not yet recruiting |
NCT06462079 -
Sacituzumab Govitecan Combined With Head Radiotherapy for Her2-negative Breast Cancer Brain Metastases
|
Phase 2 | |
| Not yet recruiting |
NCT02832635 -
A Clinical Trial on Whole-brain Radiotherapy With Temozolomide Concurrent Chemotherapy or Avoidance of Hippocampus for Patients of Brain Metastases
|
Phase 2 | |
| Completed |
NCT01395407 -
Phase I Trial of Stereotactic Radiosurgery Following Surgical Resection of Brain Metastases
|
Phase 1 |